Document is current
Any future updates will be listed below
-
Authors
Evans, Lewis D https://orcid.org/0000-0001-7279-7651
Strano, Alessio
Tuck, Eleanor
Campbell, Ashley
Smith, James https://orcid.org/0000-0001-9131-5849
Hung, Christy https://orcid.org/0000-0003-0056-7587
Behr, Tiana S https://orcid.org/0000-0001-8832-8411
Ghetti, Bernardino
Ryskeldi-Falcon, Benjamin
Karakoc, Emre
Iorio, Francesco https://orcid.org/0000-0001-7063-8913
Reith, Alastair https://orcid.org/0000-0001-5092-0604
Bassett, Andrew R https://orcid.org/0000-0003-1632-9137
Livesey, Frederick J https://orcid.org/0000-0001-6128-3372
-
Funding
Funding for this research was provided by:
OpenTargets (OTAR036)
Alzheimer's Research UK (Stem Cell Research Centre)
Wellcome Trust (WT101052MA)
Great Ormond Street Hospital Charity (Stem Cell Professorship)
NIHR | NIHR Great Ormond Street Hospital Biomedical Research Centre (N/A)
- License Information
-
More Information
Article History
Received: 27 January 2025
Revised: 2 July 2025
Accepted: 3 July 2025
First Online: 11 August 2025
Disclosure and competing interests statement
: Open Targets is a public–private partnership between non-profit research institutions and the pharmaceutical industry. FJL is a founder and holds equity in Gen2 Neuroscience and Talisman Therapeutics.
